GSK (GSK) — Upcoming Catalysts
FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for GSK, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.
For informational purposes only — not investment advice. Track GSK live on Mooboard →
No upcoming catalysts in the public data lanes right now.
How GSK has moved — past-year price reactions
How binary is GSK? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.
- +7.3%2026-02-04no matched headline
- -5.6%2026-04-29no matched headline
- +5.4%2025-10-01no matched headline
- +5.1%2025-10-29no matched headline
- -5.1%2025-10-24no matched headline
- +5%2025-09-30no matched headline
Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.
GSK — active clinical pipeline
GSK's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.
Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).
See the full biopharma catalyst calendar across all covered companies.